PODD Insulet Corp
Price (delayed)
$282.8
Market cap
$19.86B
P/E Ratio
47.37
Dividend/share
N/A
EPS
$5.97
Enterprise value
$20.29B
Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod
Highlights
PODD's net income has surged by 103% year-on-year
The EPS has soared by 102% YoY
PODD's price to earnings (P/E) is 98% lower than its 5-year quarterly average of 2614.5 but 12% higher than its last 4 quarters average of 42.3
Key stats
What are the main financial stats of PODD
Market
Valuations
Earnings
Shares outstanding
70.23M
Market cap
$19.86B
Enterprise value
$20.29B
Price to earnings (P/E)
47.37
Price to book (P/B)
16.37
Price to sales (P/S)
9.57
EV/EBIT
59.16
EV/EBITDA
47.88
EV/Sales
9.79
Revenue
$2.07B
Gross profit
$1.45B
Operating income
$308.9M
Net income
$418.3M
EBIT
$342.9M
EBITDA
$423.7M
Free cash flow
$296.3M
Per share
Balance sheet
Liquidity
EPS
$5.97
EPS diluted
$5.78
Free cash flow per share
$4.23
Book value per share
$17.27
Revenue per share
$29.56
TBVPS
$41.92
Total assets
$3.09B
Total liabilities
$1.88B
Debt
$1.38B
Equity
$1.21B
Working capital
$1.36B
Debt to equity
1.14
Current ratio
3.58
Quick ratio
2.5
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
20.5%
Gross margin
69.8%
Net margin
20.2%
Operating margin
14.9%
Return on assets
14.4%
Return on equity
40.6%
Return on invested capital
12.2%
Return on capital employed
13.4%
Return on sales
16.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PODD stock price
How has the Insulet stock price performed over time
Intraday
-1.9%
1 week
0.8%
1 month
2.43%
1 year
46.92%
YTD
8.32%
QTD
8.32%
Financial performance
How have Insulet's revenue and profit performed over time
Revenue
$2.07B
Gross profit
$1.45B
Operating income
$308.9M
Net income
$418.3M
Gross margin
69.8%
Net margin
20.2%
PODD's net income has surged by 103% year-on-year
The company's net margin has surged by 66% YoY but it fell by 4.7% QoQ
Insulet's operating income has increased by 40% YoY
PODD's gross profit is up by 25% YoY and by 5% from the previous quarter
Growth
What is Insulet's growth rate over time
Valuation
What is Insulet stock price valuation
P/E
47.37
P/B
16.37
P/S
9.57
EV/EBIT
59.16
EV/EBITDA
47.88
EV/Sales
9.79
The EPS has soared by 102% YoY
PODD's price to earnings (P/E) is 98% lower than its 5-year quarterly average of 2614.5 but 12% higher than its last 4 quarters average of 42.3
The equity has soared by 65% YoY and by 8% QoQ
PODD's price to book (P/B) is 55% less than its 5-year quarterly average of 36.5 but 11% more than its last 4 quarters average of 14.8
PODD's price to sales (P/S) is 30% lower than its 5-year quarterly average of 13.6 but 23% higher than its last 4 quarters average of 7.8
PODD's revenue is up by 22% year-on-year and by 4.4% since the previous quarter
Efficiency
How efficient is Insulet business performance
The return on assets has surged by 69% year-on-year but it has declined by 4.6% since the previous quarter
Insulet's return on invested capital has increased by 26% YoY
PODD's ROE is up by 18% YoY but it is down by 12% QoQ
The ROS has grown by 12% YoY but it has contracted by 2.4% from the previous quarter
Dividends
What is PODD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PODD.
Financial health
How did Insulet financials performed over time
The total assets is 65% higher than the total liabilities
The total assets rose by 19% YoY and by 2.1% QoQ
Insulet's quick ratio has increased by 6% YoY
The company's debt is 14% higher than its equity
The equity has soared by 65% YoY and by 8% QoQ
The debt to equity has decreased by 41% YoY and by 9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.